<DOC>
	<DOCNO>NCT02779140</DOCNO>
	<brief_summary>This Phase I , randomize , double-blind , placebo control dose escalation trial evaluate NTM-1632 three dose cohort ( A : 0.033 mg/kg , B : 0.165 mg/kg , C : 0.33 mg/kg ) . NTM-1632 mixture three monoclonal antibody design treat botulinum neurotoxin BoNT/B poisoning adult . Dose cohorts A , B , C randomize 2:6 , placebo : therapeutic , total study population 24 . The study duration project approximately 8 month , subject participation cohort A approximately 13 week , subject participation cohort B C approximately 17 week . The primary objective study assess safety tolerability escalate dos NTM-1632 administer intravenously healthy adult .</brief_summary>
	<brief_title>Phase I , Dose Escalation Study Evaluate Safety Pharmacokinetics NTM-1632</brief_title>
	<detailed_description>This Phase I , randomize , double-blind , placebo control dose escalation trial evaluate NTM-1632 three dose cohort ( A : 0.033 mg/kg , B : 0.165 mg/kg , C : 0.33 mg/kg ) . NTM-1632 mixture three monoclonal antibody design treat botulinum neurotoxin BoNT/B poisoning adult . Dose cohorts A , B , C randomize 2:6 , placebo : therapeutic , total study population 24 . The study duration project approximately 8 month , subject participation cohort A approximately 13 week , subject participation cohort B C approximately 17weeks . The primary objective study assess safety tolerability escalate dos NTM-1632 administer intravenously healthy adult . The secondary objective 1 ) ass pharmacokinetic characteristic NTM-1632 follow single intravenous administration 2 ) ass immunogenicity NTM-1632 follow single intravenous administration .</detailed_description>
	<mesh_term>Botulism</mesh_term>
	<criteria>1 . Informed consent understood sign 2 . Healthy male healthy , nonpregnant , nonlactating female 3 . Willingness comply available protocol procedure include inpatient confinement 3648 hour 4 . Age 18 45 year , inclusive day infusion 5 . Body Mass Index ( BMI ) &gt; /=18.5 &lt; /=30 kg/m2 6 . If subject female childbearing potential , negative serum pregnancy test screen negative urine test within 24 hour prior infusion . Note : A woman consider childbearing potential unless postmenopausal ( &gt; /= 1 year without menses ) surgically sterilize via bilateral oophorectomy , hysterectomy bilateral tubal ligation successful Essure placement document confirmation test least 3 month procedure . 7 . If subject female childbearing potential , agree practice abstinence sexual intercourse men use acceptable contraception , visit 12 study . Note : Acceptable contraception method restrict effective device ( Intrauterine Contraceptive Devices , NuvaRing® ) license hormonal product use method minimum 28 day prior dose , condom diaphragm spermicidal agent , monogamous relationship vasectomize partner . 8 . The hemoglobin , platelet count , white blood cell count absolute neutrophil count within normal limit 9 . The urine dipstick result protein , glucose blood negative trace . Note : Menstruating female fail inclusion criterion due positive blood urine dipstick may retested follow cessation menses . 10 . Chemistry screen laboratory test outline Section 7.5.1.4 normal reference range . Note : The following exception laboratory normal reference range allow : Creatinine , Blood Urea Nitrogen ( BUN ) , total bilirubin , AST , ALT , chloride , lipase , amylase , Prothrombin Time ( PT ) , Partial Thromboplastin Time ( PTT ) low limit normal ( LLN ) ; CK le 400mg/ml ; Glucose , potassium , CO2 , total protein , alkaline phosphatase toxicity grade 1 allowable ; Chlorides albumin upper limit normal ( ULN ) . Laboratory value outside range eligibility think due acute condition due laboratory error may repeat . Abnormalities mean corpuscular volume ( MCV ) , mean corpuscular hemoglobin ( MCH ) , mean corpuscular hemoglobin concentration ( MCHC ) , red cell distribution width ( RDW ) , mean platelet volume ( MPV ) , nucleate red blood cell count ( NRBC CT ) , include complete blood count differential , exclusion . 11 . Has adequate venous access infusion 12 . The urine drug screen negative 13 . Breathalyzer test negative 14 . Available followup duration study . 15 . Agrees participate vigorous activity 72 hour prior dose day 15 post dosing . 1 . History chronic medical condition would either interfere accurate assessment objective study increase risk profile subject . Note : Chronic medical condition include diabetes ; Asthma require use medication year screening ; Autoimmune disorder lupus , Wegener 's , rheumatoid arthritis , thyroid disease ; Coronary artery disease ; Chronic hypertension ; History malignancy except lowgrade ( squamous basal cell ) skin cancer think cure ; chronic renal , hepatic , pulmonary , endocrine disease ( except previous asthma require treatment past year ) ; 2 . History severe allergic reaction type medication , bee sting , food , environmental factor hypersensitivity reaction immunoglobulin . Note : Severe allergic reaction define follow : anaphylaxis , urticaria , angioedema 3 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 millisecond ) 4 . Clinically significant abnormal electrocardiogram screening . Note : Clinically significant abnormal ECG result include : complete leave right bundle branch block ; ventricular conduction block ; 2nd degree 3rd degree atrioventricular ( AV ) block ; sustain ventricular arrhythmia ; sustain atrial arrhythmia ; two Premature Ventricular Contractions row ; pattern ST elevation felt consistent cardiac ischemia ; condition deem clinically significant study investigator 5 . Positive serology result HIV , HBsAg , HCV antibodies 6 . Febrile illness temperature &gt; 37.6°C within 7 day dose 7 . Pregnant breastfeed 8 . Donated blood within 56 day enrollment 9 . Known allergic reaction study product component present formulation processing , list Investigator Brochure 10 . Treatment another investigational drug within 28 day dose 11 . Treatment monoclonal antibody time past 12 . Receipt antibody ( e.g . TIG , VZIG , IVIG , IM gamma globulin ) blood transfusion within 6 month within 5 halflives specific product give 13 . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement 14 . Use H1 antihistamine betablockers within 5 day dose 15 . Use prohibit medication within 28 day prior study entry plan use study period Note : Prohibited medication include immunosuppressive ( except Nonsteroidal AntiInflammatory Drugs [ NSAIDS ] ) ; immune modulators ; oral corticosteroid ( topical/intranasal steroid acceptable ) ; antineoplastic agent ; vaccine ( licensed investigational ) 16 . Previous exposure botulinum toxin , receipt antibody botulinum toxin , previous treatment equine antitoxin 17 . Any previous injection plan injection within 4 month enrollment botulinum toxin cosmetic reason , spastic dysphonia , torticollis , reason 18 . Any specific condition judgment investigator precludes participation could affect subject safety 19 . Plans enroll already enrol another clinical trial* could interfere safety assessment investigational product time study period . Note : Includes trial study intervention drug , biologic , device 20 . Is study site employee staff pay entirely partially OCRR contract DMIDfunded trial . Note : Site employee staff include PIs subinvestigators staff supervise PI SubInvestigators 21 . Systolic blood pressure &gt; 140 mm Hg diastolic blood pressure &gt; 90 mm Hg 22 . Resting heart rate &lt; 50 &gt; 100 beat per minute 23 . Oral temperature = 38°C ( 100.4°F )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 6, 2016</verification_date>
	<keyword>BoNT</keyword>
	<keyword>botulinum</keyword>
	<keyword>Botulism</keyword>
	<keyword>Clostridium</keyword>
	<keyword>Neurotoxin</keyword>
	<keyword>NTM-1632</keyword>
</DOC>